Fresh analysis indicates that individuals who stop using new weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass much more quickly than those who end traditional lifestyle plans.
Findings released in a prominent health publication shows that while overweight people frequently drop about a fifth of their body weight while on the medication, the mass is regained at an estimated rate of nearly a kilo each month upon discontinuation.
"Individuals purchasing these medications should be cognizant of the potential of rapid weight regain when the therapy is stopped," warns expert Dr. Susan Jebb.
That rate of recovery suggests a return to original weight within about one and a half years.
Analyzing Approaches
The research, which reviewed 37 of trials involving over 9,000 of participants, contrasted the outcomes of GLP-1 agonists with older methods.
The team emphasize that people who shed pounds through diet and exercise typically see a more gradual weight regain—perhaps 0.1 kg a month—once they finish.
The Reason for the Fast Rebound
Experts believe the mode of action of the drugs accounts for the amplified rebound.
GLP-1 drugs copy a natural hormone called GLP-1, which helps regulate hunger.
"Long-term administration of GLP-1 levels several times higher than the body's typical production could lead to the body to generate a reduced amount of its endogenous GLP-1, and could reduce sensitivity to its actions," explained Dr. Adam Collins, a nutrition expert.
"Discontinuation of this hormone supplement means appetite is uncontrolled, making binge eating much more probable."
A Lifelong Condition?
Medical guidelines advise the jabs for individuals with obesity-related health risks, alongside recommended lifestyle changes.
Many experts argue that, considering the significant potential of relapse, the therapy is often ongoing.
This perspective is supported by pharmaceutical companies, who say that the results "emphasize the long-term nature of excess weight," akin to managing diseases like high blood pressure.
User Testimonies
Individuals who have stopped the medication describe a intense resurgence of cravings.
"It was like a trigger flipping and you're instantly extremely hungry," described one woman.
This difficulty is exacerbated if individuals have not adopted sustainable dietary or behavioural modifications during therapy.
Growing Adoption
Figures indicate that a significant number of people in the UK have used these injections in the past year, with demand remaining high.
- Adoption is more common among women than men.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion access the drugs through private healthcare rather than the NHS.
In conclusion, experts emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a magic cure and maintained weight loss likely depends on ongoing behavioural management.
